Emergency Liver Retransplantation With Marginal Donors

Transplant Proc. 2023 Dec;55(10):2282-2284. doi: 10.1016/j.transproceed.2023.09.012. Epub 2023 Nov 14.

Abstract

Background: The goal of the present study is to determine if using marginal donors negatively impacts the outcomes of emergency liver retransplantation.

Methods: A retrospective case-control study was performed, including all emergency liver retransplantations done in our center between 1990 and 2021. Recipients from the control group received the second grafts from "ideal donors", and patients from the case group received them from marginal donors. Analyzed variables included demographics of recipients and donors, complications, and survival rates.

Results: 38 emergency retransplantations were performed. 23 recipients were included in the control group, and the remaining 15 were in the case group. The second donors from the case group were significantly older (mean age 58 vs 71 years old, P < 0.0001). On the contrary, there were no differences between groups regarding the mean age of recipients, comorbidities, Model for End-Stage Liver Disease scores, or causes of retransplantation (the most common was hepatic artery thrombosis). No differences were found in early perioperative death rates (control group 26.1% vs case group 20%, P =1) and, although the case group seemed to have slightly poorer outcomes in long-term survival (control group 70%, 61%, and 55% vs case group 73%, 59%, and 39%, respectively, at 1, 5, and 10 years), the differences were not statistically significant (log-rank = 0.808).

Conclusions: The use of marginal donors for emergency liver retransplantation was proved safe in our study, as there were no differences in complications or in short- or mid-term survival rates.

MeSH terms

  • Aged
  • Case-Control Studies
  • End Stage Liver Disease* / surgery
  • Graft Survival
  • Humans
  • Liver Transplantation* / adverse effects
  • Middle Aged
  • Reoperation
  • Retrospective Studies
  • Severity of Illness Index
  • Tissue Donors
  • Treatment Outcome